FDA says Xolair associated with CV events in interim safety analysis
This article was originally published in Scrip
Executive Summary
Initial findings of a safety study of Novartis/Genentech's asthma drug Xolair (omalizumab) have found a disproportionate increase in cardiovascular and cerebrovascular events in patients taking Xolair compared with those on placebo.